XML 37 R44.htm IDEA: XBRL DOCUMENT v2.4.0.6
Technology Licensing Agreements (Details) (USD $)
1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Aug. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Feb. 28, 2011
License Agreement with AstraZeneca UK Limited [Member]
Integer
Feb. 28, 2007
License Agreement with AstraZeneca UK Limited [Member]
Dec. 31, 2011
License Agreement with AstraZeneca UK Limited [Member]
Dec. 31, 2010
License Agreement with AstraZeneca UK Limited [Member]
Dec. 31, 2009
License Agreement with AstraZeneca UK Limited [Member]
Dec. 31, 2008
License Agreement with AstraZeneca UK Limited [Member]
Dec. 31, 2007
License Agreement with AstraZeneca UK Limited [Member]
Aug. 31, 2010
License Agreement with Astellas Pharma Inc [Member]
Mar. 31, 2007
License Agreement with Astellas Pharma Inc [Member]
Dec. 31, 2011
License Agreement with Astellas Pharma Inc [Member]
Dec. 31, 2010
License Agreement with Astellas Pharma Inc [Member]
Dec. 31, 2009
License Agreement with Astellas Pharma Inc [Member]
Dec. 31, 2008
License Agreement with Astellas Pharma Inc [Member]
Dec. 31, 2007
License Agreement with Astellas Pharma Inc [Member]
Deferred Revenue Arrangement [Line Items]                                    
Non-exclusive license agreement term (in years)           6Y             6Y          
Annual, non-refundable licensing payment received               $ 20,000,000 $ 20,000,000 $ 20,000,000 $ 20,000,000       $ 20,000,000 $ 20,000,000 $ 20,000,000 $ 20,000,000
Period over which annual payment is recognized as revenue (in months)               12M 12M 12M 12M              
Number of annual payments not received due to cancellation of obligation         2                          
Advance payment received due to amended licensing agreement with Astellas Pharma Inc 165,000,000                                  
Recognition period for advance payment (in years)                       7Y            
Future payment to be made to the Company under the terms of the amended licensing agreement                             130,000,000      
Number of days of advance written notice to terminate agreement (in days)                             90D      
Technology licensing revenue recognized   24,858,000 40,150,000 40,013,000     2,900,000 20,000,000 20,000,000         22,000,000 20,000,000 20,000,000    
Deferred revenue                           $ 151,700,000 $ 173,700,000